Clinical Trial

Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring

Study acronym: ATP-HCM
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
* Validation of validity, superiority, and safety of data analysis results using AT-Patch compared to 48-hour Holter test results * Number of subjects: 100 (including 10% dropout rate) * Performance and safety were verified by simultaneously attaching a 48-hour Holter and a wearable Holter device (ATP-C75 or ATP-C135).
Trial Details
NCT Number NCT06873828
Lead Sponsor Yonsei University
Conditions Hypertrophic Cardiomyopathy
Enrollment 100 participants
Start Date 2025-03
Primary Completion 2025-10 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-03-13